Population pharmacokinetic evaluation of a fully human IgG2 monoclonal antibody in patients with inflammatory diseases

Inflammation and Allergy - Drug Targets

Volumn 9, Issue 4, 2010, Pages 229-237

  Tabrizi, Mohammad ^a,b   Wang, Bing ^a,c   Lu, Hong ^a,c   Huang, Saling ^a,d   Bell, Gregory ^a,d   Schwab, Gisela ^a,e   Roskos, Lorin ^a,c  

^a AMGEN INC   (United States)

^b AnaptysBio Inc   (United States)

^c Medimmune Inc   (United States)

^d KAI Pharmaceuticals   (United States)

^e EXELIXIS INC   (United States)

Author keywords

Anti IL8 monoclonal antibody; Interleukin 8; Patients with inflammatory diseases; Pharmacokinetics

Indexed keywords

DRUG ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; INTERLEUKIN 8; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ABX IL8; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING AFFINITY; BODY WEIGHT; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; FEMALE; HUMAN; IMMUNOASSAY; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION RESEARCH; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; STEADY STATE;

EID: 79751499823     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152810793358796     Document Type: Article

References (44)

1. Monoclonal Antibodies: Update. Datamonitor, 2008.
2. Medicines in development: Biotechnology. PhRMA Report, 2008. Available from: http://www.phrma.org/files/attachments/Biotech%202008.pdf [Accessed August 01, 2010].
3. Reichert, J.M. Antibodies to watch. mAbs, 2010, 2, 84-100.
4. Reichert, J.M. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol., 2008, 9, 423-430.
5. Weiner, L.M.; Surana, R.; Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev., 2010, 10, 317-327.
6. Tabrizi, M.; Bornstein, G.G.; Suria, H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J, 2010, 12, 33-43.
7. Tabrizi, M.; Roskos, L.K. In: Pharmacokinetics and Pharmacodynamics of Biotech Drugs, Bernd, M.; Ed.; WILEYVCH, 2006, pp. 295-327.
8. Tabrizi, M.; Funelas, C.; Suria, H. Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J, 2010, DOI: 10.1208/S12248-010-9220-2.
9. Tabrizi, M.; Bornstein, G.G.; Klakamp, S.L.; Drake, A., Knight, R.; Roskos, L. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov. Today, 2009, 14, 298-305.
10. Tabrizi, M.; Tseng, C.M.; Roskos, L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today, 2006, 11, 81-88.
11. ®(Panitumumab) PrescribingInformation:http://www.vectibix.com/prescribing_information/prescribing_information.html [Accessed August 01, 2010].
12. Gibson, T.B.; Ranganathan, A.; Grothey, A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin. Colorectal Cancer, 2006, 6, 29-31.
13. Ma, P.; Yang, B.B.; Wang, Y.M.; Peterson, M.; Narayanan, A.; Sutjandra, L. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J. Clin. Pharmacol., 2009, 49, 1142-56.
14. Prolia™ (Denosumab), Prescribinginformation.http://pi.amgen.com/united_states/prolia/prolia_pi.pdf [Accessed August 01, 2010]
15. Peterson, M.; Stouch, B.; Chen, D.; Baughman, S.; Holloway, D.; Bekker, P. A population PK/PD model describes the rapid, and sustained suppression of urinary n-telopeptidetelopeptide following administration of AMG 162, a fully human monoclonal antibody against RANK L, to healthy postmenopausal women http://www.aapspharmaceutica.com/inside/focus_groups/poppk/imagespdfs/PopPKPD-2004Final.pdf [Accessed August 01, 2010].
16. Yang, X.D.; Corvalan, J.R.; Wang, P.; Roy, C.M.; Davis, C.G. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J. Leukoc. Biol., 1999, 66, 401-410.
17. Huang, S.; Mills, L.; Mian, B.; Tellez, C.; McCarty, M.; Yang, X.D. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol., 2002, 16,125-134.
18. Xu, Z.; Vu, T.; Lee, H.; Hu, C.; Ling, J.; Yan, H. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-{alpha} human monoclonal antibody, in patients with psoriatic arthritis. J. Clin. Pharmacol., 2009, 49,1056-1070.
19. Zhou, H.; Hu, C., Zhu, Y.; Lu, M., Liao, S.; Yeilding, N. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J. Clin. Pharmacol., 2009, 50, 257-267.
20. Nussler, A.K.; Wittel, U.A.; Nussler, N.C.; Beger, H.G. Leukocytes, the Janus cells in inflammatory disease. Langenbeck's Archives of Surgery/Deutsche Gesellschaft fur Chirurgie 1999, 384, 222-232.
21. Baggiolini M. Chemokines and leukocyte traffic. Nature, 1998, 392, 565-568.
22. Strieter, R.M.; Koch, A.E.; Antony, V.B.; Fick, R.B.; Standiford, T.J.; Kunkel, S.L. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J. Lab. Clin. Med., 1994, 123, 183-197.
23. Mahler, D.A.; Huang, S.; Tabrizi, M.; Bell, G.M. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest. 2004, 126, 926-934.
24. Tabrizi, M.; Roskos, L.; Osborn, K.; Lu, H.; Pasumarthi, R.; Raie, N. Pharmacokinetics of ABX-IL8 in patients with psoriasis following administration of weight-adjusted and fixed doses. AAPS Annual Meeting, Salt Lake City UT, USA. 2003.
25. Wang, B.; Roskos, L.; Osborn, K.; Lu, H.; Kim, M.; Pasumarthi, R. A population pharmacokinetic (PK) analysis of ABX-IL8, a fully human monoclonal IgG2 antibody in psoriasis patients. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, USA. 2005.
26. Hayashida, K.; Nanki, T.; Girschick, H.; Yavuz, S.; Ochi, T.; Lipsky, P.E. Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Arthritis Res., 2001, 3, 118-126.
27. Skov, L.; Beurskens, F.J.; Zachariae, C.O.; Reitamo, S.; Teeling, J.; Satijn, D. IL-8 as an antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J. Immunol, 2008, 181, 669-679.
28. Akahoshi, T.; Endo, H.; Kondo, H.; Kashiwazaki, S.; Kasahara, T.; Mukaida, N. Essential involvement of interleukin-8 in neutrophil recruitment in rabbits with acute experimental arthritis induced by lipopolysaccharide and interleukin-1. Lymphokine Cytokine Res., 1994, 13, 113-6.
29. Lu, H., Tabrizi, M.; Roskos, L., Pasumarthi, R., Funelas, C., Holtzclaw, S. Development, validation, and application of enzymelinked immunosorbent assays for determination of ABX-IL8 pharmacokinetic and immunogenicity profiles in patients with psoriasis and rheumatoid arthritis, AAPS Annual Meeting, Baltimore, MD, USA. 2004.
30. Liang, M.; Klakamp, S.L.; Funelas, C.; Lu, H.; Lam, B.; Herl, C.; Roskos L.K. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev. Technol., 2007, 5, 655-662.
31. Klakamp, S.L.; Lu, H.; Tabrizi, M.; Funelas, C.; Roskos, L.K.; Coleman, D. Application of analytical detection concepts to immunogenicity testing. Anal. Chem., 2007, 79, 8176-8184.
32. Tabrizi, M.A.; Roskos, L.K. Preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today, 2007, 12, 540-7.
33. Tabrizi, M.; Suria, H. Application of translational biomarkers in development of antibody-based therapeutics. Drug Discov., 2009, 6, 36-40.
34. Morell, A.; Terry, W.D.; Waldmann, T.A. Metabolic properties of IgG subclasses in man. J. Clin. Investig., 1970, 49, 673-680.
35. Spiegelberg, H.L.; Fishkin, B.G.; Grey, H.M. Catabolism of human gammaG-immunoglobulins of different heavy chain subclasses in man. J. Clin. Investig., 1968, 47, 2323-2330.
36. Waldmann, T.A.; Strober, W. Metabolism of immunoglobulins. Prog. Allergy, 1969, 13, 1-110.
37. Garg, A.; Balthasar, J.P. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J. Pharmacokinet. Pharmacodyn., 2007, 34, 687-709.
38. Lobo, E.D.; Hansen, R.J.; Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci., 2004, 93, 2645-2668.
39. ® (Adalimumab) Prescribing Information http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm092762.pdf [Accessed August 01, 2010].
40. Brambell, F.W. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet, 1966, 19, 1087-1093.
41. Waldmann T.A. Immunoglobulins: Biological Aspects and Clinical Uses, National Academy of Sciences, 1970.
42. Ghetie, V.; Ward, E.S. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol. Today, 1997, 18, 592-598.
43. Junghans, RP. IgG biosynthesis: no immunoregulatory feedback. Blood, 1997, 90, 3815-8.
44. Roskos, L.K.; Kellermann, S-A.; Foon, K.A. In Measuring Immunity: Basic Science and Clinical Practice; Lotze, M.T.; Thompson AW, Ed.; Elsevier Academic Press, London 2005, pp. 172-186.